People · Operator
Named in public records as an officer, director or promoter · active 2014–2019 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2019 |
| ClassPass Inc. | — | Other Technology | Series C | $159.5M | $157.1M | 2017 |
| Syntimmune, Inc. | — | Biotechnology | Series B | $26.0M | $714.4M | 2014 |
Sam Hall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sam Hall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 1 | 19 |
| Jerel Davis | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| Geeta Vemuri | 1 | 7 |
| Adam Valkin | 1 | 7 |
| Michael Farello | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Tanzeen Syed | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Andrew King | 1 | 3 |
| Robert Mylod | 1 | 3 |
| Paul Eisenberg | 1 | 2 |
| Preston Klassen | 1 | 2 |
| Justin Chang | 1 | 2 |
| Richard Lanman | 1 | 2 |
| Srini Akkaraju | 1 | 2 |
| DAVID DE GRAAF, PH.D. | 1 | 2 |
| Michael Wolf | 1 | 2 |
| Seth Harrison, M.D. | 1 | 1 |
| Alan Federman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.